Mouse Monoclonal ATP2A1 Antibody

+ +

•  

   
     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

•  

   
     Western blot analysis using ATP2A1 mouse mAb against C2C12 (1), COS7 (2), Hela (3), K562 (4), and Jurkat (5) cell lysate.    

•  

   
     Flow cytometric analysis of HeLa cells using ATP2A1 mouse mAb (green) and negative control (red).    

The ATP2A1 antibody targets the ATP2A1 gene product, also known as sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (SERCA1), a critical enzyme responsible for transporting calcium ions from the cytosol into the sarcoplasmic reticulum (SR) in skeletal muscle cells. This P-type ATPase maintains low cytosolic calcium levels during muscle relaxation, enabling proper contraction-relaxation cycles. SERCA1 is predominantly expressed in fast-twitch skeletal muscle fibers, and its dysfunction is linked to muscle disorders like Brody myopathy, a rare autosomal recessive condition characterized by exercise-induced muscle stiffness and impaired calcium reuptake.

ATP2A1 antibodies are widely used in research to study SERCA1 expression, localization, and regulatory mechanisms in muscle physiology. They aid in detecting protein levels via Western blotting, immunohistochemistry, or immunofluorescence, helping to elucidate SERCA1's role in calcium homeostasis and muscle pathology. These antibodies also contribute to investigating SERCA1 mutations, post-translational modifications (e.g., phosphorylation), and interactions with regulatory proteins like phospholamban. Commercially available ATP2A1 antibodies are typically raised in rabbits or mice, validated for specificity in human, rodent, or other model organisms. Their applications extend to preclinical studies of muscle-related diseases and therapeutic interventions targeting calcium signaling pathways.